- Home
- SNDX vs NWBI Comparison
SNDX vs NWBI Comparison
Compare SNDX & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNDX | NWBI |
|---|---|---|
| Founded | 2005 | 1896 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2014 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SNDX | NWBI |
|---|---|---|
| Price | $23.51 | $12.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $84.17 | $13.67 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 05-04-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 6.35% |
| EPS Growth | 11.56 | ★ 16.46 |
| EPS | N/A | ★ 0.92 |
| Revenue | ★ $172,352,000.00 | N/A |
| Revenue This Year | $107.40 | $6.29 |
| Revenue Next Year | $43.28 | $5.06 |
| P/E Ratio | ★ N/A | $13.70 |
| Revenue Growth | ★ 627.84 | N/A |
| 52 Week Low | $8.59 | $10.75 |
| 52 Week High | $25.59 | $13.62 |
Technical Indicators
Market Signals| Indicator | SNDX | NWBI |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 48.06 |
| Support Level | $19.46 | $11.93 |
| Resistance Level | $25.16 | $12.91 |
| Average True Range (ATR) | 1.12 | 0.29 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 22.01 | 44.67 |
Price Performance
Historical ComparisonAbout SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.